146 related articles for article (PubMed ID: 37863558)
21. A survival guide to HER2 testing in gastric/gastroesophageal junction carcinoma.
Subasinghe D; Acott N; Kumarasinghe MP
Gastrointest Endosc; 2019 Jul; 90(1):44-54. PubMed ID: 30928424
[TBL] [Abstract][Full Text] [Related]
22. Advances in the management of HER2-positive advanced gastric and gastroesophageal junction cancer.
Bang YJ
J Clin Gastroenterol; 2012 Sep; 46(8):637-48. PubMed ID: 22751336
[TBL] [Abstract][Full Text] [Related]
23. HER2/neu (ERBB2) expression and gene amplification correlates with better survival in esophageal adenocarcinoma.
Plum PS; Gebauer F; Krämer M; Alakus H; Berlth F; Chon SH; Schiffmann L; Zander T; Büttner R; Hölscher AH; Bruns CJ; Quaas A; Loeser H
BMC Cancer; 2019 Jan; 19(1):38. PubMed ID: 30621632
[TBL] [Abstract][Full Text] [Related]
24.
Klempner SJ; Madison R; Pujara V; Ross JS; Miller VA; Ali SM; Schrock AB; Kim ST; Maron SB; Dayyani F; Catenacci DVT; Lee J; Chao J
Oncologist; 2019 Nov; 24(11):1462-1468. PubMed ID: 31249137
[TBL] [Abstract][Full Text] [Related]
25. HER2 expression and relevant clinicopathological features in gastric and gastroesophageal junction adenocarcinoma in a Chinese population.
Shan L; Ying J; Lu N
Diagn Pathol; 2013 May; 8():76. PubMed ID: 23656792
[TBL] [Abstract][Full Text] [Related]
26. Esophageal and esophagogastric junction cancers, version 1.2015.
Ajani JA; D'Amico TA; Almhanna K; Bentrem DJ; Besh S; Chao J; Das P; Denlinger C; Fanta P; Fuchs CS; Gerdes H; Glasgow RE; Hayman JA; Hochwald S; Hofstetter WL; Ilson DH; Jaroszewski D; Jasperson K; Keswani RN; Kleinberg LR; Korn WM; Leong S; Lockhart AC; Mulcahy MF; Orringer MB; Posey JA; Poultsides GA; Sasson AR; Scott WJ; Strong VE; Varghese TK; Washington MK; Willett CG; Wright CD; Zelman D; McMillian N; Sundar H;
J Natl Compr Canc Netw; 2015 Feb; 13(2):194-227. PubMed ID: 25691612
[TBL] [Abstract][Full Text] [Related]
27. Gastroesophageal Junction Adenocarcinoma: Is There an Optimal Management?
Lin D; Khan U; Goetze TO; Reizine N; Goodman KA; Shah MA; Catenacci DV; Al-Batran SE; Posey JA
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():e88-e95. PubMed ID: 31099690
[TBL] [Abstract][Full Text] [Related]
28. Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients.
Fuse N; Kuboki Y; Kuwata T; Nishina T; Kadowaki S; Shinozaki E; Machida N; Yuki S; Ooki A; Kajiura S; Kimura T; Yamanaka T; Shitara K; Nagatsuma AK; Yoshino T; Ochiai A; Ohtsu A
Gastric Cancer; 2016 Jan; 19(1):183-91. PubMed ID: 25682441
[TBL] [Abstract][Full Text] [Related]
29. Immuno-Oncology Biomarkers for Gastric and Gastroesophageal Junction Adenocarcinoma: Why PD-L1 Testing May Not Be Enough.
Weinberg BA; Xiu J; Hwang JJ; Shields AF; Salem ME; Marshall JL
Oncologist; 2018 Oct; 23(10):1171-1177. PubMed ID: 29703766
[TBL] [Abstract][Full Text] [Related]
30. EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group.
Wagner AD; Grabsch HI; Mauer M; Marreaud S; Caballero C; Thuss-Patience P; Mueller L; Elme A; Moehler MH; Martens U; Kang YK; Rha SY; Cats A; Tokunaga M; Lordick F
BMC Cancer; 2019 May; 19(1):494. PubMed ID: 31126258
[TBL] [Abstract][Full Text] [Related]
31. Biomarker-driven targeted therapies for gastric/gastro-esophageal junction malignancies.
Kim S; Barzi A; Rajdev L
Semin Oncol; 2018 Jun; 45(3):133-150. PubMed ID: 30262395
[TBL] [Abstract][Full Text] [Related]
32. Association between HSP90 and Her2 in gastric and gastroesophageal carcinomas.
Berezowska S; Novotny A; Bauer K; Feuchtinger A; Slotta-Huspenina J; Becker K; Langer R; Walch A
PLoS One; 2013; 8(7):e69098. PubMed ID: 23874879
[TBL] [Abstract][Full Text] [Related]
33. Circulating Tumor DNA Sequencing Analysis of Gastroesophageal Adenocarcinoma.
Maron SB; Chase LM; Lomnicki S; Kochanny S; Moore KL; Joshi SS; Landron S; Johnson J; Kiedrowski LA; Nagy RJ; Lanman RB; Kim ST; Lee J; Catenacci DVT
Clin Cancer Res; 2019 Dec; 25(23):7098-7112. PubMed ID: 31427281
[TBL] [Abstract][Full Text] [Related]
34. Perioperative treatment and biomarker analysis of LP002, an anti-PD-L1 antibody, plus chemotherapy in resectable gastric and gastroesophageal junction cancer.
Tang JL; Zhang B; Xu JP; Qi L; Xin D; Wang L; Wang BZ; Tian YT; Li Y; Huang J
Cancer Med; 2023 Mar; 12(5):5639-5648. PubMed ID: 36341590
[TBL] [Abstract][Full Text] [Related]
35. HER2/neu gene amplification and protein overexpression in gastric and gastroesophageal junction adenocarcinoma: a review of histopathology, diagnostic testing, and clinical implications.
Hechtman JF; Polydorides AD
Arch Pathol Lab Med; 2012 Jun; 136(6):691-7. PubMed ID: 22646280
[TBL] [Abstract][Full Text] [Related]
36. FDA Approval Summary: Pembrolizumab for Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD-L1.
Fashoyin-Aje L; Donoghue M; Chen H; He K; Veeraraghavan J; Goldberg KB; Keegan P; McKee AE; Pazdur R
Oncologist; 2019 Jan; 24(1):103-109. PubMed ID: 30120163
[TBL] [Abstract][Full Text] [Related]
37. Adenocarcinoma at the gastroesophageal junction.
Al-Haddad S; Chang AC; De Hertogh G; Grin A; Langer R; Sagaert X; Salemme M; Streutker CJ; Soucy G; Tripathi M; Upton MP; Vieth M; Villanacci V
Ann N Y Acad Sci; 2014 Sep; 1325():211-25. PubMed ID: 25266027
[TBL] [Abstract][Full Text] [Related]
38. 'All action no talk': the role of HER2/neu in adjuvant therapy choice for gastric cancer.
Santini D; Vincenzi B; Pantano F; Schiavon G; Tonini G
Ann Oncol; 2013 Jul; 24(7):1715-1717. PubMed ID: 23670095
[No Abstract] [Full Text] [Related]
39. HER2 amplification status in gastric and gastro-oesophageal junction cancer in routine clinical practice: which sample should be used?
Perrone G; Amato M; Callea M; Rabitti C; Righi D; Crucitti P; Coppola R; Onetti Muda A
Histopathology; 2012 Jul; 61(1):134-5. PubMed ID: 22551459
[No Abstract] [Full Text] [Related]
40. Validation of a DKK1 RNAscope chromogenic in situ hybridization assay for gastric and gastroesophageal junction adenocarcinoma tumors.
Caldwell C; Rottman JB; Paces W; Bueche E; Reitsma S; Gibb J; Adisetiyo V; Haas MS; Heath H; Newman W; Baum J; Gianani R; Kagey MH
Sci Rep; 2021 May; 11(1):9920. PubMed ID: 33972574
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
